| Literature DB >> 26339223 |
Mang Ou-Yang1, Yao-Fang Hsieh2, Cheng-Chung Lee2.
Abstract
Cytopathological examination through biopsy is very important for carcinoma detection. The embedded relay lens microscopic hyperspectral imaging system (ERL-MHIS) provides a morphological image of a biopsy sample and the spectrum of each pixel in the image simultaneously. Based on the ERL-MHIS, this work develops morphological and spectral methods to diagnose oral carcinoma biopsy. In morphological discrimination, the fractal dimension method is applied to differentiate between normal and abnormal tissues. In spectral identification, normal and cancerous cells are distinguished using five methods. However, the spectra of normal and cancerous cells vary with patient. The diagnostic performances of the five methods are thus not ideal. Hence, the proposed cocktail approach is used to determine the effectiveness of the spectral methods in correlating with the sampling conditions. And then we use a combination of effective spectral methods according to the sample conditions for diagnosing a sample. A total of 68 biopsies from 34 patients are analyzed using the ERL-MHIS. The results demonstrate a sensitivity of 90 ± 4.53 % and a specificity of 87.8 ± 5.21 %. Furthermore, in our survey, this system is the first time utilized to study oral carcinoma biopsies.Entities:
Keywords: Biopsy; Hyperspectral imaging; Microscopy; Oral carcinoma
Year: 2015 PMID: 26339223 PMCID: PMC4551557 DOI: 10.1007/s40846-015-0052-5
Source DB: PubMed Journal: J Med Biol Eng ISSN: 1609-0985 Impact factor: 1.553
Fig. 1a Diagram and b photograph of ERL-MHIS (RL relay lens, HS hyperspectrometer, SM stepping motor, IMP1 imaging plane 1, IMP2 imaging plane 2, FW fluorescent wheel
Fig. 3Difference of mean fluorescent emission spectrum of cells between normal and various oral cancer stages on tongue (patients 7, 12, 24, and 26). Mean fluorescence emission spectra of normal cells and cancer cells under (a) F1 and (b) F2 excitation
Fractal dimension value of normal and cancer tissues
| No. | 1 | 2 | 3 | 4 | 5 | 6 | 7 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FD | PR | PVR | AUS1 | AUS2 | FWHM | Combination | |||||||||||||
| Nor | Can | Sn. | Sp. | Cpoint | Sn. | Sp. | Cpoint | Sn. | Sp. | Cpoint | Sn. | Sp. | Cpoint | Sn. | Sp. | Cpoint | Sn. | Sp. | |
| 1 | 1.73 | 1.90 | 89.2 | 81.5 | 1.45 | 61.2 | 69.3 | 1.46 | 84.5 | 84.6 | 285 | 64.4 | 56.9 | 133 | 75.3 | 81.6 | 67 | 91.7 | 85.4 |
| 2 | 1.72 | 1.82 | 83.5 | 87.2 | 1.52 | 78.5 | 60.3 | 1.51 | 81.3 | 92.1 | 275 | 74.4 | 49.5 | 144 | 78.9 | 45.8 | 64 | 88.3 | 80.3 |
| 3 | 1.57 | 1.88 | 98 | 90.1 | 1.94 | 98.9 | 90.1 | 1.71 | 82.5 | 70.1 | 303 | 81.1 | 73.9 | 130 | 82.2 | 70.1 | 57.5 | 96.4 | 88.2 |
| 4 | 1.69 | 1.78 | 60.1 | 72.4 | 1.65 | 49.8 | 70.1 | 2.21 | 84.2 | 80.3 | 234 | 66.2 | 78.1 | 126 | 82.5 | 98.3 | 50.8 | 82.3 | 97.6 |
| 5 | 1.24 | 1.80 | 80.1 | 68.2 | 2.01 | 49.8 | 80.3 | 1.68 | 67.5 | 78.4 | 219 | 98 | 98.5 | 151 | 96.5 | 94.3 | 77 | 96.5 | 95.3 |
| 6 | 1.65 | 1.85 | 79.6 | 56.4 | 1.45 | 80.2 | 50.1 | 1.98 | 89.6 | 90.1 | 235 | 68.7 | 71.9 | 120 | 66.5 | 51.2 | 60.7 | 95.1 | 93.2 |
| 7 | 1.66 | 1.97 | 77.9 | 68.5 | 1.68 | 92.3 | 88.9 | 1.09 | 79.6 | 77.5 | 211 | 80.3 | 71.4 | 110 | 89.2 | 80.3 | 42 | 86.3 | 83.4 |
| 8 | 1.68 | 1.85 | 70.3 | 67.9 | 2.27 | 80.3 | 77.5 | 1.33 | 88.6 | 87.3 | 203 | 72.3 | 46.4 | 124 | 76.5 | 80.3 | 70 | 90.3 | 90.1 |
| 9 | 1.59 | 1.89 | 66.7 | 59.1 | 2.19 | 67.1 | 77.2 | 1.54 | 40.8 | 65.1 | 203 | 94.3 | 92.3 | 130 | 91.6 | 88.2 | 73 | 95.4 | 89.6 |
| 10 | 1.66 | 1.86 | 81.3 | 80.5 | 2.82 | 70.2 | 68.5 | 1.9 | 79.1 | 66.4 | 186 | 70.2 | 65.2 | 114 | 70.1 | 50.3 | 58.3 | 84.2 | 80.2 |
| 11 | 1.5 | 1.76 | 79.1 | 67.4 | 2.67 | 82.1 | 80.1 | 1.44 | 45.2 | 77.1 | 199 | 81.6 | 86.7 | 122 | 83.5 | 70.1 | 71 | 80.2 | 87.4 |
| 12 | 1.58 | 1.91 | 82.1 | 80.4 | 1.38 | 79.4 | 67.1 | 1.75 | 87.6 | 85.3 | 262 | 77.6 | 58.9 | 122 | 81.3 | 70.5 | 55.3 | 88.5 | 82.1 |
| 13 | 1.34 | 1.92 | 89.1 | 50.6 | 1.62 | 88.3 | 80.1 | 1.88 | 88.1 | 78.4 | 222 | 78.3 | 45.2 | 156 | 97.1 | 99.3 | 56 | 92.3 | 80.2 |
| 14 | 1.26 | 1.87 | 89.3 | 70.1 | 1.73 | 80.2 | 84.3 | 1.45 | 79.2 | 62.1 | 256 | 88.5 | 49.7 | 145 | 80.2 | 81.2 | 76 | 89.5 | 90.1 |
| 15 | 1.35 | 1.86 | 80.1 | 85.8 | 1.48 | 72.3 | 68.4 | 1.60 | 88.3 | 90.1 | 292 | 80.1 | 42.3 | 166 | 99 | 92.1 | 72 | 96.3 | 89.1 |
| 16 | 1.56 | 1.82 | 79.4 | 40.5 | 2.33 | 68.3 | 67.3 | 1.45 | 80.2 | 94.1 | 222 | 98.3 | 88.4 | 187 | 70.3 | 68.5 | 66 | 91.2 | 80.1 |
| 17 | 1.67 | 1.93 | 80.2 | 60.1 | 1.67 | 92.3 | 91.4 | 1.43 | 88.1 | 89.6 | 201 | 40.5 | 40.1 | 131 | 39.6 | 76.4 | 58 | 86.3 | 88.9 |
| 18 | 1.62 | 1.82 | 79.2 | 50.1 | 1.31 | 90.7 | 88.6 | 1.55 | 90.3 | 87.2 | 254 | 88.3 | 66 | 143 | 90.2 | 96.4 | 70 | 92.3 | 94.5 |
| 19 | 1.65 | 1.86 | 70.2 | 78.3 | 1.58 | 88.3 | 90.2 | 1.38 | 89.4 | 90.2 | 223 | 80.2 | 81.4 | 129 | 88.2 | 78 | 60 | 92.1 | 88.5 |
| 20 | 1.34 | 1.90 | 88.1 | 79.3 | 1.41 | 50.2 | 50.6 | 1.43 | 84.3 | 83.2 | 234 | 90.1 | 59.1 | 156 | 90.2 | 80.4 | 62 | 88.2 | 89.4 |
| 21 | 1.23 | 1.91 | 60.1 | 84.2 | 1.91 | 56.4 | 87.4 | 1.33 | 88.6 | 90.2 | 200 | 56.4 | 67.3 | 133 | 80.7 | 82.3 | 55 | 90.3 | 80.2 |
| 22 | 1.32 | 1.95 | 87.3 | 89.2 | 1.21 | 70.2 | 78.5 | 1.67 | 70.2 | 74.5 | 224 | 60.3 | 59.7 | 145 | 80.2 | 38.5 | 78 | 85.4 | 88.5 |
| 23 | 1.72 | 1.78 | 50.2 | 71.3 | 1.23 | 80.2 | 89.4 | 1.45 | 55.4 | 68.3 | 267 | 79.1 | 70.2 | 165 | 69.3 | 80.1 | 80 | 86.2 | 80.1 |
| 24 | 1.56 | 1.80 | 85.3 | 92.1 | 1.58 | 95.6 | 88.3 | 1.49 | 80.1 | 80.1 | 256 | 77.5 | 80.2 | 158 | 78.1 | 89.1 | 68 | 90.1 | 92.3 |
| 25 | 1.45 | 1.82 | 67.1 | 80.3 | 1.78 | 88.4 | 70.1 | 1.23 | 87.2 | 90.1 | 203 | 88.2 | 89.3 | 129 | 90.1 | 65.1 | 48 | 89.1 | 90.2 |
| 26 | 1.33 | 1.84 | 80.3 | 98.2 | 1.21 | 88.3 | 89.4 | 1.44 | 99.4 | 98.3 | 278 | 80.2 | 88.1 | 162 | 77.1 | 80.2 | 72 | 90.4 | 93.1 |
| 27 | 1.56 | 1.87 | 80.1 | 81.2 | 1.24 | 49.1 | 44.3 | 1.11 | 30.4 | 99.2 | 245 | 50.1 | 82.1 | 121 | 74.1 | 86.2 | 66 | 85.3 | 84.3 |
| 28 | 1.67 | 1.97 | 84.1 | 90 | 2.34 | 95.2 | 92.1 | 1.23 | 80.2 | 80.1 | 234 | 80.1 | 80 | 145 | 78.4 | 72.1 | 48 | 99.7 | 93.2 |
| 29 | 1.56 | 1.95 | 88.3 | 85.2 | 1.72 | 90.2 | 97.2 | 1.09 | 87.3 | 87.5 | 241 | 86.9 | 89.3 | 111 | 49.2 | 77.1 | 56 | 90.2 | 91.4 |
| Mean |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| STD |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sensitivity, specificity, and cut-off point of spectrum-based methods for distinguishing normal and cancer cells of 29 patients for training
AUS1 area under spectral curve normalized by the intensity of peak 1, AUS2 area under spectral curve normalized by the intensity of peak 2, FD fractal dimension, FWHM full width at half maximum of spectral curve, PR peak ratio, PVR peak and valley ratio, Sn sensitivity, Sp. specificity, Cpoint cut-off point of each sample, STD standard deviation
Fig. 4Flow chart of combination approach determining most effective methods
Patient information
| Group | Patient no. | Age | Site | T | N | Stage | Number of nuclei | |
|---|---|---|---|---|---|---|---|---|
| Normal | Cancer | |||||||
| Training | 1 | 71 | Tongue | 2 | 2 | IV | 555 | 478 |
| 2 | 50 | Tongue | 2 | 2 | IV | 158 | 156 | |
| 3 | 41 | Mucosa | 1 | 0 | I | 260 | 164 | |
| 4 | 42 | Gum | 2 | 2 | IV | 250 | 200 | |
| 5 | 44 | Gum | 1 | 0 | I | 102 | 200 | |
| 6 | 52 | Gum | 4 | 2 | IV | 166 | 160 | |
| 7 | 64 | Tongue | 1 | 0 | I | 360 | 400 | |
| 8 | 67 | Mucosa | 3 | 0 | III | 200 | 179 | |
| 9 | 51 | Pyriform sinus | 4 | 2 | IV | 133 | 578 | |
| 10 | 56 | Gum | 2 | 0 | II | 333 | 299 | |
| 11 | 47 | Pyriform sinus | 3 | 2 | III | 255 | 399 | |
| 12 | 51 | Tongue | 2 | 0 | II | 209 | 108 | |
| 13 | 56 | Mucosa | 3 | 0 | III | 300 | 367 | |
| 14 | 63 | Palate | 2 | 0 | II | 432 | 333 | |
| 15 | 50 | Tongue | 2 | 2 | IV | 589 | 601 | |
| 16 | 57 | Gum | 4 | 2 | IV | 200 | 309 | |
| 17 | 52 | Tongue | 2 | 0 | II | 378 | 678 | |
| 18 | 37 | Tongue | 1 | 2 | IV | 409 | 561 | |
| 19 | 78 | Tongue | 2 | 0 | II | 444 | 500 | |
| 20 | 60 | Tongue | 2 | 2 | IV | 400 | 266 | |
| 21 | 80 | Tongue | 1 | 0 | I | 289 | 260 | |
| 22 | 52 | Palate | 2 | 0 | II | 178 | 256 | |
| 23 | 65 | Mucosa | 2 | 0 | II | 300 | 457 | |
| 24 | 60 | Tongue | 3 | 0 | III | 398 | 457 | |
| 25 | 34 | Tongue | 1 | 0 | I | 405 | 302 | |
| 26 | 43 | Tongue | 2 | 2 | IV | 298 | 390 | |
| 27 | 61 | Palate | 4 | 0 | IV | 203 | 599 | |
| 28 | 32 | Mucosa | 1 | 0 | I | 592 | 212 | |
| 29 | 56 | Mucosa | 1 | 0 | I | 402 | 700 | |
| Testing | 30 | 65 | Mucosa | 2 | 0 | N/A | 214 | 692 |
| 31 | 41 | Tongue | 1 | 0 | N/A | 299 | 401 | |
| 32 | 31 | Mucosa | 1 | 0 | N/A | 272 | 459 | |
| 33 | 48 | Tongue | 2 | 3 | N/A | 393 | 598 | |
| 34 | 37 | Mucosa | 2 | 0 | N/A | 505 | 496 | |
The number of nuclei are those in the basal-cell layer
T Tthe size or direct extent of the primary tumor, T1, T2, T3, and T4 The size and/or extension of the primary tumor, N The degree of spread to regional lymph nodes, N0 The tumor cells are absent from regional lymph nodes, N1 The regional lymph node metastasis is present, N2 The tumor has spread to an extent between N1 and N3, N3 The tumor has spread to more distant or numerous regional lymph nodes
Fig. 2Biopsy image of patient 7. a Transmission image of normal tissue. Fluorescence images of normal tissue under (b) F1 and (c) F2 excitation. d Binary image of normal tissue for calculating fraction dimension. e Transmission image of cancerous tissue. Fluorescence images of cancerous tissue under (f) F1 and (g) F2 excitation. h Binary image of cancerous tissue for calculating fraction dimension
Correlation between effective methods and patient’s conditions
| Age | 30–39 | 40–49 | 50–59 | 60–69 | 70–80 |
|---|---|---|---|---|---|
| Method | PVR (1.34), AUS1 (230.3) | AUS2 (138.2), FWHM (65.7) | AUS1 (233) | FWHM (66.3) | AUS1 (236), FWHM (60.7) |
| Site | Tongue | Mucosa | Gum | Palate | Pyriform sinus |
| Method | AUS1 (242.6) | PVR (1.45) | AUS1 (219.2), AUS2 (139.6) | PVR (1.41) | AUS2 (126) |
| T | T1 | T2 | T3 | T4 | |
| Method | PVR (1.36), AUS1 (233.1) | AUS1 (247.5) | PVR (1.54), FWHM (66.3) | AUS2 (139.5) | |
| N | N0 | N2 | |||
| Method | PVR (1.46) | AUS1 (246.5) |
Number in parentheses is optimal cut-off point of each effect method under different condition
T The size or direct extent of the primary tumor, T1, T2, T3, and T4 The size and/or extension of the primary tumor, N The degree of spread to regional lymph nodes. N0 The tumor cells absent from regional lymph nodes, N1 The regional lymph node metastasis present, N2 The tumor spreads to an extent between N1 and N3, N3 The tumor spreads to more distant or numerous regional lymph nodes
Fig. 5Comparison of performance of all methods. (a) Mean sensitivity and (b) mean specificity of 29 patients for each method